Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić
Formato:	Artigo
Idioma:	English
Publicado em:	Elsevier 2023-12-01
coleção:	Translational Oncology
Assuntos:	Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1936523323001857

Registros relacionados

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
por: Hana Garaj, et al.
Publicado em: (2024-01-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
por: Senar Ebinç, et al.
Publicado em: (2023-09-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
por: Wu L, et al.
Publicado em: (2021-02-01)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
por: Katarina Mirjačić Martinović, et al.
Publicado em: (2023-04-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
por: Dugan MM, et al.
Publicado em: (2024-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
por: Polsky David, et al.
Publicado em: (2004-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
por: Francesca Consoli, et al.
Publicado em: (2020-07-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
por: Jacek Calik, et al.
Publicado em: (2024-01-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Justin C. Moser, et al.
Publicado em: (2019-12-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
por: Xiang Dan, et al.
Publicado em: (2024-04-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
por: I. V. SAMOILENKO, et al.
Publicado em: (2017-06-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
por: Ernesto Rossi, et al.
Publicado em: (2023-01-01)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
por: Lance Wollenberg, et al.
Publicado em: (2023-10-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
por: Bartoušková Marie, et al.
Publicado em: (2020-08-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
por: Yu. S. Shakh-Paronyants, et al.
Publicado em: (2023-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
por: Dahlia Fedele, et al.
Publicado em: (2024-01-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Saba S. Shaikh, et al.
Publicado em: (2022-11-01)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
por: Milena Cavic, et al.
Publicado em: (2023-04-01)

Melanoma: BRAFi Rechallenge
por: Christoforos S. Kosmidis, et al.
Publicado em: (2023-05-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
por: Rozala Arko, et al.
Publicado em: (2022-07-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian S, et al.
Publicado em: (2018-08-01)

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
por: Lazaro Hiram Betancourt, et al.
Publicado em: (2021-07-01)

Current State of Target Treatment in BRAF Mutated Melanoma
por: Enrica Teresa Tanda, et al.
Publicado em: (2020-07-01)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
por: Marco Ghezzi, et al.
Publicado em: (2020-03-01)

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
por: Ahmed Temirak, et al.
Publicado em: (2025-02-01)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives
por: Peter Mohr, et al.
Publicado em: (2025-03-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
por: Karam Khaddour, et al.
Publicado em: (2021-06-01)

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
por: Igor V. Samoylenko, et al.
Publicado em: (2024-10-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
por: Adi Kartolo, et al.
Publicado em: (2022-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
por: Simeng Zhang, et al.
Publicado em: (2023-01-01)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
por: Clara So, et al.
Publicado em: (2022-05-01)

Braf protein mutation and its significancy within patients with melanoma
por: Julia Kuchnicka, et al.
Publicado em: (2022-08-01)

Treatment of Advanced Melanoma: Past, Present and Future
por: Taku Fujimura, et al.
Publicado em: (2020-09-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
por: Elodie Long-Mira, et al.
Publicado em: (2022-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
por: Walid Shalata, et al.
Publicado em: (2023-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
por: Nakul Dar, et al.
Publicado em: (2023-08-01)

Tyrosine kinase inhibitors via nasogastric tube may resolve severe ileus secondary to melanoma: A case report
por: Lena Groennendijk, et al.
Publicado em: (2022-06-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
por: Francesco Serra, et al.
Publicado em: (2021-08-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
por: O. I. Kit, et al.
Publicado em: (2016-06-01)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
por: Sim Vermeulen, et al.
Publicado em: (2021-04-01)